Arterium Brings Tramix Anti-Haemorrhagic Drug Product to the Market

A new anti-haemorrhagic drug product, Tramix, solution for injection was introduced to the Ukrainian market in February.

The drug provides a systemic haemostatic effect in cases of haemorrhages, associated with fibrinolysis growth. The drug also possesses anti-inflammatory, anti-allergic, and anti-infectious effect. The tranexamic acid presented in the drug’s composition provides an analgesic effect and is capable of enhancing the painkilling action of the opiates.

Tramix is produced by Galychpharm, PJSC, (which is)a part  of Arterium Corporation, in accordance with requirements and regulations of Good Manufacturing Practice () harmonized with EU legislation.

 Arterium Corporation appreciates the State Expert Centre’s and Ministry’s of Health timely examination and  registrationof the drugin Ukraine.

This information is intended solely for medical and pharmaceutical professionals. You can find the detailed information on the drug product in the instruction for use.

This website is a specialized information resource designed for medical and pharmaceutical professionals.